Rezolute, Inc. (RZLT)

Rezolute Reports First Quarter Fiscal 2022 Financial Results and Highlights Recent Company Progress

View Press Release View All

Oct 13, 2021 • 8:10am EDT

Rezolute Announces Pricing of Public Offering of $55 million of Common Stock and Pre-Funded Warrants, and Concurrent Registered Direct Offering

Oct 12, 2021 • 4:05pm EDT

Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants, and a Concurrent Registered Direct Offering

Sep 22, 2021 • 4:05pm EDT

Rezolute Presents Results from Two-Week Natural History Study in Congenital Hyperinsulinism Patients on Standard of Care Therapies at ESPE 2021

Corporate Presentation – January 2022

View Presentation

Q1 2022

Quarter Ended Sep 30, 2021

Earnings Release

10-Q

PDF HTML

XBRL

ZIP XLS HTML

Latest Annual Filing

For Fiscal Year Ending Jun 30, 2021

IR Contacts

Company

Rezolute, Inc.
201 Redwood Shores Pkwy
Suite 315
Redwood City, CA 94065
T: +1 (650) 206-4507

Investor Relations

investor-relations@rezolutebio.com

Media

media-relations@rezolutebio.com

Transfer Agent

Direct Transfer LLC, a subsidiary of Issuer Direct Corp. (NYSE)
1 Glenwood Ave
Suite 1001
Raleigh, NC 27603-2582
F: 919-744-2722
transfer@issuerdirect.com

Market Data copyright © 2022 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.

MENU